BMO Capital Downgrades Graphite Bio to Market Perform, Lowers Price Target to $7

Benzinga · 01/06/2023 10:04
BMO Capital analyst Kostas Biliouris downgrades Graphite Bio (NASDAQ:GRPH) from Outperform to Market Perform and lowers the price target from $14 to $7.